

PBS XML Release Notes

Effective date: 1st April 2016

Release 2

PBS XML Schema version: 2.12

Changes from Release 1:

1. Correct the listing of the subcutaneous trastuzumab. The new trastuzumab subcutaneous PBS listing from 1 April 2016 will remain under the section 100 Efficient Funding of Chemotherapy Drugs arrangements, changing from the TZ/TY program (“special authority items”) to the CT program (“related benefits” schedule). The related benefits drugs schedule does not include fees such as diluent and compounding which are not relevant to a ready-prepared presentation.
2. Delete Item – Optive Sensitive eye drops: solution, 30 x 0.4 mL unit doses from PR5561Q and 9307W.
3. Correct ex-manufacturer price for Lamivudine with zidovudine from \$367.72 to \$367.62
4. Changed the Safety net status on 55 Community Access program items from “Yes” to “No”

10266H	10271N	10272P	10273Q
10274R	10275T	10276W	10283F
10284G	10285H	10286J	10287K
10294T	10297Y	10298B	10299C
10300D	10301E	10303G	10304H
10305J	10307L	10310P	10311Q
10312R	10313T	10314W	10318C
10319D	10320E	10321F	10326L
10327M	10329P	10335Y	10336B
10337C	10344K	10345L	10347N
10348P	10349Q	10350R	10351T
10355B	10356C	10357D	10360G
10361H	10363K	10364L	10365M
10366N	10367P	10692R	

5. Renamed organisation ‘bioCSL’ to ‘Seqirus (Australia) Pty Ltd’.

Known Issues

1. Some changes to Maximum Patient Charge amounts may not be the subject of a pbs:alteration element.

2. Redundant @amount attributes for pbs:vial-content and pbs:pack-content elements have been removed.